SYN 023

Drug Profile

SYN 023

Alternative Names: CTB 011/CTB 012; CTB 012/CTB 011; SYN-023

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synermore Biologics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Rabies

Most Recent Events

  • 13 Oct 2016 Discontinued - Phase-I for Rabies in China (IM)
  • 01 Aug 2016 Phase-II clinical trials in Rabies (In volunteers) in USA (IM) (NCT02956746)
  • 30 Jun 2016 Synermore Biologics completes a phase I trial in Rabies in USA (Synermore Biologics pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top